AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The EPIC study, officially titled A Non-interventional, Observational Cohort Study of Chronic Lymphocytic Leukaemia Patients Treated With Acalabrutinib in the First-line Setting Through the UK Early Access Programme, aims to assess real-world outcomes for patients with chronic lymphocytic leukaemia (CLL) in the UK. The study’s primary objective is to estimate progression-free survival, while secondary objectives include overall survival and response rates, among others. This research is significant as it provides UK-specific data on the effectiveness of acalabrutinib in a real-world setting.
Acalabrutinib, the intervention being tested, is a drug used to treat patients with CLL. It is administered to patients as part of the first-line treatment through the UK Early Access Programme, aiming to improve survival rates and treatment responses.
The study is observational, utilizing a cohort model with a retrospective time perspective. It does not involve random allocation or masking, focusing on collecting real-world data from clinical records to achieve its objectives.
The study began on October 17, 2022, with its primary completion and estimated completion dates yet to be announced. The last update was submitted on June 27, 2025. These dates are crucial as they mark the progress and anticipated conclusion of the study, providing timelines for data availability and analysis.
The update on the EPIC study could positively impact AstraZeneca’s stock performance by reinforcing investor confidence in the company’s innovative treatments for CLL. As the study progresses, it may also influence the competitive landscape, highlighting AstraZeneca’s commitment to addressing unmet needs in oncology.
The EPIC study is ongoing, with further details available on the ClinicalTrials portal.